Poseida Therapeutics, Inc.
PSTX · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $49 | $31 | $53 | $44 |
| Short-Term Investments | $182 | $207 | $145 | $168 |
| Receivables | $15 | $12 | $12 | $9 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $5 | $4 | $6 | $5 |
| Total Curr. Assets | $251 | $254 | $217 | $226 |
| Property Plant & Equip (Net) | $36 | $38 | $39 | $41 |
| Goodwill | $4 | $4 | $4 | $4 |
| Intangibles | $1 | $1 | $1 | $1 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $1 | $1 | $1 | $1 |
| Total NC Assets | $43 | $44 | $46 | $47 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $294 | $299 | $263 | $274 |
| Liabilities | – | – | – | – |
| Payables | $5 | $3 | $3 | $3 |
| Short-Term Debt | $6 | $12 | $6 | $12 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $37 | $63 | $50 | $31 |
| Other Curr. Liab. | $30 | $24 | $26 | $25 |
| Total Curr. Liab. | $78 | $102 | $85 | $71 |
| LT Debt | $77 | $78 | $79 | $79 |
| Deferred Rev, NC | $0 | $55 | $12 | $17 |
| Deferred Tax Liab, NC | $0 | $19 | $20 | $21 |
| Other NC Liab. | $51 | $3 | $3 | $3 |
| Total NC Liab. | $128 | $135 | $93 | $99 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $24 | $25 | $26 | $27 |
| Total Liabilities | $206 | $238 | $178 | $170 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$630 | -$650 | -$619 | -$594 |
| AOCI | $0 | -$0 | -$0 | $0 |
| Other Equity | $717 | $711 | $703 | $698 |
| Total Equity | $87 | $61 | $85 | $104 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $294 | $299 | $263 | $274 |
| Net Debt | $33 | $59 | $31 | $47 |